Details for Patent: 4,978,672

Summary for Patent: 4,978,672

Title:	Alpha-heterocyclc substituted tolunitriles
Abstract:	The invention is concerned with aromatase inhibiting compounds of formula I ##STR1## wherein R and Ro represent hydrogen or lower alkyl; or R and Ro located on adjacent carbon atoms and together when combined with the benzene ring to which they are attached form a naphthalene or tetrahydronaphthalene ring; R1 and R2 independently represent hydrogen, lower alkyl, (lower alkyl, aryl or aryl-lower alkyl)-thio, lower alkenyl, aryl, aryl-lower alkyl, C3 -C6 -cycloalkyl, or C3 -C6 -cycloalkyl-lower alkyl; or R1 and R2 combined represent lower alkylidene, mono- or di-aryl-lower alkylidene; R1 and R2 combined also represent C4 -C6 -straight chain alkylene, lower alkyl-substituted straight chain alkylene or ortho-phenylene bridged-C2 -C4 -straight chain alkylene, each forming with the carbon atom attached thereto a corresponding optionally substituted or benzo-fused 5, 6 or 7-membered ring; W represents 1-imidazolyl, 1-(1,2,4- or 1,3,4)-triazolyl or 3-pyridyl; or W represents 1-imidazolyl, 1-(1,2,4 or 1,3,4)-triazolyl or 3-pyridyl substituted by lower alkyl; and pharmaceutically acceptable salts thereof.
Inventor(s):	Robert M. Bowman, Ronald E. Steele, Leslie Browne
Assignee:	Novartis Pharmaceuticals Corp
Application Number:	US07/240,862
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 4,978,672

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,978,672

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0236940		SPC/GB97/013	United Kingdom
European Patent Office	0236940		97C0053	Belgium
European Patent Office	0236940		C970011	Netherlands
Austria	94873
Australia	604011